✦ LIBER ✦

Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination

✍ Scribed by Brian I. Lord; Nydia G. Testa; Sergio Bretti; James Chang; Hilda Demuynck; Lucia Coutinho; Edson De Campos; Lesley Fitzsimmons; J. Howard Scarffe

Publisher: John Wiley and Sons
Year: 1994
Tongue: French
Weight: 839 KB
Volume: 59
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.2910590409

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interleukin-3 and granulocyte-macrophage

Interleukin-3 and granulocyte-macrophage colony-stimulating factor in combination: Clinical implication

✍ Frisch, Jürgen ;Ganser, Arnold ;Hoelzer, Dieter ;Brugger, Wolfram ;Kanz, Lothar 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB

The multilineage hematopoietic effects of IL-3 appear to be most important for its clinical use comprising especially leucocyte and platelet responses. This was demonstrated to be dose dependent characterising doses of 250 to 500 micrograms/m2/day subcutaneously as hematopoietic effective and well t

Recombinant human granulocyte-colony sti

Recombinant human granulocyte-colony stimulating factor and recombinant human macrophage colony stimulating factor synergize in vivo to enhance proliferation of granulocyte-macrophage, erythroid, and multipotential progenitor cells in mice

✍ Hal E. Broxmeyer; Douglas E. Williams; Scott Cooper; Giao Hangoc; Peter Ralph 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

Combinations of low dosages of purified recombinant human (rh) macrophagecolony stimulating factor (M-CSF; also termed CSF-1) and rh granulocyte-colony stimulating factor (G-CSF) were compared alone and in combination for their influence on the cycling rates and numbers of bone marrow and splenic gr

Treatment of de novo acute myelogenous l

Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts

✍ Valent, Peter ;Sillaber, Christian ;Geissler, Klaus ;Andreeff, Michael ;Tafuri, 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB

GM-CSF is a major regulator of myelopoiesis. Recombinant human GM-CSF (250 micrograms/m2 per day i.v.) was used prior to chemotherapy ("3 + 7" scheme) to recruit leukemic blasts in vivo (de novo AML patients, n = 20) into the chemotherapy sensitive phases of the cell cycle. The stimulatory effect of

Sequential interleukin 3 and granulocyte

Sequential interleukin 3 and granulocyte-macrophage–colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

✍ Hillary H. Wu; Moshe Talpaz; Richard E. Champlin; Susan R. Pilat; Razelle Kurzro 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

## Background: Interleukin-3 (il-3) and granulocyte-macrophage-colony stimulating factor (gm-csf) have synergistic, hematopoietic growth-promoting activity in preclinical studies. because of the paucity of effective therapies for patients with chronic bone marrow failure states, the authors studied

Recombinant murine granulocyte-macrophag

Recombinant murine granulocyte-macrophage (GM) colony-stimulating factor supports formation of GM and multipotential blast cell colonies in culture: Comparison with the effects of interleukin-3

✍ Kenichi Koike; Makio Ogawa; James N. Ihle; Takaji Miyake; Tomoe Shimizu; Atsushi 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 808 KB

We studied the effects of murine recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) on murine hemopoiesis in methylcellulose culture. The GM-CSF was purified from cultures of Saccharomyces cerevisiae transfected with a cloned murine GM-CSF cDNA. In cultures of spleen cells from no

Granulocyte-macrophage–colony stimulatin

Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f